Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy.
Dendritic cells are professional antigen-presenting cells that initiate, regulate and shape the induction of specific immune responses. The ability to use dendritic cells in the induction of antigen-specific tolerance, antigen-specific immunity or specific differentiation of T-helper subsets holds great promise in dendritic cell-based immunotherapy of various diseases such as cancer, viral infections, allergy, as well as autoimmunity. Replication-incompetent HIV-1-based lentiviral vector is now emerging as a promising delivery system to genetically modify dendritic cells through antigen recognition, costimulatory molecules and/or polarization signals for the manipulation of antigen-specific immunity in vivo. This article discusses some of the recent advances in the uses of lentiviral vectors in dendritic cell-based immunotherapy.
Wang
Huiming
H
University of Manitoba, Department of Immunology, Room 417 Apotex Center, 750 McDermot Avenue, Winnipeg, Manitoba, R3E 0T5, Canada.
Zhang
Liang
L
Kung
Sam K P
SK
D000818:Animals; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000276:immunology* / Q000821:virology; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000502:physiology*; D006801:Humans; D007109:Immunity; D016219:Immunotherapy, Adoptive; D016086:Lentivirus / Q000235:genetics* / Q000472:pathogenicity; D016180:Lentivirus Infections / Q000235:genetics* / Q000276:immunology